27 February 2012. London UK. A new report by visiongain predicts that the world market for cancer-treating drugs will reach $75 billion for 2012. That revenue forecast appears in Leading Anti-Cancer Drugs and Associated Market 2012-2022, published in February 2012. Visiongain is a business information provider based in London, UK.
The new study predicts that overall revenues for anti-cancer treatments will increase strongly from 2012 to 2022. Individual drugs will benefit too. Roche will continue to be the leading company in the cancer-treating drugs market throughout the study’s forecast period. Through emerging technologies and increasing demand in developed and developing countries, the future of cancer treatments holds great promise. That revenue growth will be mainly owing to the worldwide increase in cancer incidence and prevalence. New opportunities for cancer treatment exist, with high sales likely from many drugs – small-molecule products and biological agents (biologicals) – to 2022. Also, R&D pipelines in oncology are strong, including those for monoclonal antibodies (MAbs).
The visiongain pharmaceutical industry analyst at visiongain, said, “Although oncology is one of the most researched areas of medicine, there remain un-met and under-met treatment needs. There is a need for well targeted therapies with better safety and efficacy. It is crucial that anti-cancer drugs have minimal side effects, so that the quality of patients’ lives can be enhanced. Pharma companies will further explore this field, making therapeutic progress this decade. In particular, companion diagnostic tests with drugs will help in cancer treatment, giving more-personalised, better-targeted medicine.”
Visiongain’s report provides revenue forecasts to 2022 at world market, submarket, product and national level. It forecasts world sales for the following submarkets:
• Traditional antineoplastic agents
• Novel antineoplastic agents
• Hormone therapies
• Other agents.
That investigation forecasts sales of 25 leading drugs in the anti-cancer treatment market, including Avastin, Rituxan, Herceptin and Glivec/Gleevec. The study also assesses eight recently approved drugs. Research, data and analyses cover activities of Roche, Novartis, AstraZeneca, Eli Lilly, Celgene and other pharmaceutical companies.
The analysis includes researching the oncology R&D pipeline, interviewing authorities on the industry and forecasting revenues in leading national markets. Countries analysed are the US, Japan, the EU5 and BRIC countries. Leading Anti-Cancer Drugs and Associated Market 2012-2022 adds to visiongain’s range of analytical reports on industries and markets in healthcare.
To view sample pages of the report please click on:
For an exec summary please email Sara Peerun on: email@example.com
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Energy, Telecoms, Pharmaceutical, Defence, Materials sectors.
Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on.